Mapatumumab
Encyclopedia
Mapatumumab is a human
monoclonal antibody designed for the treatment of cancer.
This drug was discovered by Cambridge Antibody Technology
(CAT) and Human Genome Sciences
, Inc. (HGS) as a result of the collaboration between the two companies in 1999 in exploitation CAT's phage display
technology.
Early work by CAT and HGS indicated that mapatumumab induced cell death in multiple tumour types both in vitro and in vivo.
in 2004 demonstrated the safety and tolerability of mapatumumab in cancer patients with advanced solid tumors or non-Hodgkin’s lymphoma, and supported further evaluation in phase 2 clinical trials, both as a single agent and in combination with chemotherapy.
2005: In a phase 2 clinical trial mapatumumab was well tolerated and could be administered safely in patients with advanced non-small-cell lung cancer (NSCLC) and advanced colorectal cancer
. Stable disease was observed in a number of NSCLC patients.
In two phase 1b clinical trials mapatumumab in combination with chemotherapy was well tolerated by patients with advanced solid tumors. Partial response was observed in a number of patients in each of the studies.
The results of a phase 2 clinical trial demonstrated that mapatumumab was well tolerated and capable of producing clinical responses when administered as monotherapy in patients with advanced non-Hodgkin’s lymphoma, according to HGS.
in advanced multiple myeloma
. However, in 2010, mapatumumab failed in a midstage study. There was no difference in disease response or progression-free survival rates between patients receiving the drug for multiple myeloma and the control group.
and carboplatin
as first-line therapy in patients with advanced non-small-cell lung cancer (NSCLC); initial data from the study are anticipated in 2009."
) in patients with advanced hepatocellular cancer, which accounts for 80-90% of all liver cancer
s."
Human
Humans are the only living species in the Homo genus...
monoclonal antibody designed for the treatment of cancer.
This drug was discovered by Cambridge Antibody Technology
Cambridge Antibody Technology
Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, United Kingdom...
(CAT) and Human Genome Sciences
Human Genome Sciences
Human Genome Sciences is a biopharmaceutical corporation founded in 1992. It uses the human DNA sequence to develop protein and antibody drugs. As of 2008, it has drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax disease, cancer, rheumatoid...
, Inc. (HGS) as a result of the collaboration between the two companies in 1999 in exploitation CAT's phage display
Phage display
Phage display is a method for the study of protein–protein, protein–peptide, and protein–DNA interactions that uses bacteriophages to connect proteins with the genetic information that encodes them. Phage Display was originally invented by George P...
technology.
Early work by CAT and HGS indicated that mapatumumab induced cell death in multiple tumour types both in vitro and in vivo.
Clinical trials
A phase 1 clinical trialClinical trial
Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety and efficacy data to be collected for health interventions...
in 2004 demonstrated the safety and tolerability of mapatumumab in cancer patients with advanced solid tumors or non-Hodgkin’s lymphoma, and supported further evaluation in phase 2 clinical trials, both as a single agent and in combination with chemotherapy.
2005: In a phase 2 clinical trial mapatumumab was well tolerated and could be administered safely in patients with advanced non-small-cell lung cancer (NSCLC) and advanced colorectal cancer
Colorectal cancer
Colorectal cancer, commonly known as bowel cancer, is a cancer caused by uncontrolled cell growth , in the colon, rectum, or vermiform appendix. Colorectal cancer is clinically distinct from anal cancer, which affects the anus....
. Stable disease was observed in a number of NSCLC patients.
In two phase 1b clinical trials mapatumumab in combination with chemotherapy was well tolerated by patients with advanced solid tumors. Partial response was observed in a number of patients in each of the studies.
The results of a phase 2 clinical trial demonstrated that mapatumumab was well tolerated and capable of producing clinical responses when administered as monotherapy in patients with advanced non-Hodgkin’s lymphoma, according to HGS.
Multiple myeloma
In 2008 HGS reported initial results of a randomised phase 2 trial of mapatumumab in combination with bortezomibBortezomib
Bortezomib is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma...
in advanced multiple myeloma
Multiple myeloma
Multiple myeloma , also known as plasma cell myeloma or Kahler's disease , is a cancer of plasma cells, a type of white blood cell normally responsible for the production of antibodies...
. However, in 2010, mapatumumab failed in a midstage study. There was no difference in disease response or progression-free survival rates between patients receiving the drug for multiple myeloma and the control group.
Non-small-cell lung cancer
"In August 2008, ... initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (10 mg/kg or 30 mg/kg) in combination with paclitaxelPaclitaxel
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a U.S. National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol...
and carboplatin
Carboplatin
Carboplatin, or cis-Diammineplatinum is a chemotherapy drug used against some forms of cancer...
as first-line therapy in patients with advanced non-small-cell lung cancer (NSCLC); initial data from the study are anticipated in 2009."
Liver cancer
"In July 2008, HGS initiated dosing in ... a randomized Phase 2 trial of HGS-ETR1 in combination with Nexavar (sorafenibSorafenib
Sorafenib , is a drug approved for the treatment of primary kidney cancer and advanced primary liver cancer ....
) in patients with advanced hepatocellular cancer, which accounts for 80-90% of all liver cancer
Liver cancer
Liver tumors or hepatic tumors are tumors or growths on or in the liver . Several distinct types of tumors can develop in the liver because the liver is made up of various cell types. These growths can be benign or malignant...
s."